Freedman, S. ., Hercinovic, A. ., Wallace, D. K., Kraker, R. ., Li, Z. ., Bhatt, A. ., … Good, W. V. (2022). Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes. Ophthalmology, 129(10), 1120-1128. 10.1016/j.ophtha.2022.05.019 (Original work published 2022)
Deborah VanderVeen
Wallace, D. K., Kraker, R. ., Freedman, S. ., Crouch, E. ., Bhatt, A. ., Hartnett, E. ., … Investigator Group, P. E. D. . (2020). Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmology, 138(6), 698-701. 10.1001/jamaophthalmol.2020.0334 (Original work published 2020)
Wallace, D. K., Kraker, R. ., Freedman, S. ., Crouch, E. ., Hutchinson, A. ., Bhatt, A. ., … Investigator Group, P. E. D. . (2017). Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study. JAMA Ophthalmology, 135(6), 654-656. 10.1001/jamaophthalmol.2017.1055 (Original work published 2017)
VanderVeen, D. ., Bremer, D. L., Fellows, R. R., Hardy, R. J., Neely, D. ., Palmer, E. ., … Cooperative Group, E. T. F. R. O. P. C. . (2011). Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial. Journal of the American Association for Pediatric Ophthalmology and Strabismus (J AAPOS), 15(6), 536-40. 10.1016/j.jaapos.2011.07.017 (Original work published 2011)
VanderVeen, D. ., Coats, D. ., Dobson, V. ., Fredrick, D. ., Gordon, R. ., Hardy, R. J., … Cooperative Group, E. T. F. R. O. P. C. . (2006). Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study. Archives of Ophthalmology, 124(6), 766-73. 10.1001/archopht.124.6.766 (Original work published 2006)